Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 1Phase 3 1Phase 1/2 1Phase 1 1

Status

Completed 49Active not recruiting 28Unknown 18Recruiting 17Terminated 9Not yet recruiting 5Withdrawn 4

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Breast 2Head & Neck 1Gastrointestinal 1

Conditions

Triple Negative Breast Neoplasms 1Rare Tumour 1Nasopharyngeal Carcinoma 1Esophageal Squamour Cell Cancer 1Breast Neoplasms 1

Interventions

Carboplatin 79Cisplatin 74Bevacizumab 62Radiotherapy 59Drug Therapy 57Capecitabine 57Oxaliplatin 56tislelizumab 54toripalimab 45Paclitaxel 44Gemcitabine 43pembrolizumab 40anlotinib 40Specimen Handling 39sintilimab 37Cyclophosphamide 34130-nm albumin-bound paclitaxel 34Injections 30Pemetrexed 28camrelizumab 26Surgical Procedures, Operative 26Magnetic Resonance Spectroscopy 25lenvatinib 24apatinib 23Docetaxel 23Etoposide 22S 1 (combination) 21Fluorouracil 21Immune Checkpoint Inhibitors 20Biopsy 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × palbociclib × Clear all
NCT07299890 2025-12-23

An Exploratory Study of Pertuzumab and Trastuzumab in Combination With Palbociclib and Exemestane as Neoadjuvant Therapy for Triple-Positive Breast Cancer

Anhui Provincial Cancer Hospital

Phase 2 Not yet recruiting
90 enrolled
Breast

Breast Neoplasms

NCT07191977 2025-09-25

Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma

West China Hospital

Phase 2 Not yet recruiting
41 enrolled
Gastrointestinal

Esophageal Squamour Cell Cancer

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting
200 enrolled

Rare Tumour

NCT05067530 2021-10-05

CAREGIVER

Medical University of Gdansk

Phase 2 Not yet recruiting
126 enrolled
Breast

Triple Negative Breast Neoplasms

NCT04605562 2021-09-05

Umbrella Biomarker-Guided Therapy in NPC

Sun Yat-sen University

Phase 2 Not yet recruiting
206 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡